The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials
Open accessAbstract
OBJECTIVE: To analyse the benefits and harms of statins in patients with chronic kidney disease (pre-dialysis, dialysis, and transplant populations). DESIGN: Meta-analysis. DATA SOURCES: Cochrane Central Register of Controlled Trials, Medline, Embase, and Renal Health Library (July 2006). STUDY SELECTION: Randomised and quasi-randomised controlled trials of statins compared with placebo or other statins in chronic kidney disease. DATA EXTRACTION AND ANALYSIS: Two reviewers independently assessed trials for inclusion, extracted data, and assessed trial quality. Differences were resolved by consensus. Treatment effects were summarised as relative risks or weighted mean differences with 95% confidence intervals by using a random effects model. RESULTS: Fifty trials (30 144 patients) were included. Compared with placebo, statins significantly reduced total cholesterol (42 studies, 6390 patients; weighted mean difference -42.28 mg/dl (1.10 mmol/l), 95% confidence interval -47.25 to -37.32), low density lipoprotein cholesterol (39 studies, 6216 patients; -43.12 mg/dl (1.12 mmol/l), -47.85 to -38.40), and proteinuria (g/24 hours) (6 trials, 311 patients; -0.73 g/24 hour, -0.95 to -0.52) but did not improve glomerular filtration rate (11 studies, 548 patients; 1.48 ml/min (0.02 ml/s), -2.32 to 5.28). Fatal cardiovascular events (43 studies, 23 266 patients; relative risk 0.81, 0.73 to 0.90) and non-fatal cardiovascular events (8 studies, 22 863 patients; 0.78, 0.73 to 0.84) were reduced with statins, but statins had no significant effect on all cause mortality (44 studies, 23 665 patients; 0.92, 0.82 to 1.03). Meta-regression analysis showed that treatment effects did not vary significantly with stage of chronic kidney disease. The side effect profile of statins was similar to that of placebo. Most of the available studies were small and of suboptimal quality; mortality data were provided by a few large trials only. CONCLUSION: Statins significantly reduce lipid concentrations and cardiovascular end points in patients with chronic kidney disease, irrespective of stage of disease, but no benefit on all cause mortality or the role of statins in primary prevention has been established. Reno-protective effects of statins are uncertain because of relatively sparse data and possible outcomes reporting bias.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895 · cited 1×
“The number of people affected by chronic kidney disease or who need renal replacement treatment is steadily increasing.”
BackgroundSCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
PEDERSEN, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,106
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Tuomilehto, J., Vidgren, G., Toivanen, L., Tuomilehto-Wolf, E., Kohtamaki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M., & Koskela, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,692
Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients
Kalantar-Zadeh, K., Block, G., Humphreys, M. H., & Kopple, J. D. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00803.x · Cited by 1,247
Law, M. R., Wald, N. J., & Thompson, S. G. (1994) · BMJ · doi:10.1136/bmj.308.6925.367 · Cited by 1,210
GANESH, S. K., STACK, A. G., LEVIN, N. W., HULBERT-SHEARON, T., & PORT, F. K. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v12102131 · Cited by 1,204
Liu, Y., Coresh, J., Eustace, J. A., Longenecker, J. C., Jaar, B., Fink, N. E., Tracy, R. P., Powe, N. R., & Klag, M. J. (2004) · JAMA · doi:10.1001/jama.291.4.451 · Cited by 777
Hebert, P. R. (1997) · JAMA · doi:10.1001/jama.1997.03550040069040 · Cited by 740
HEBERT, P. R., GAZIANO, J. M., CHAN, K. S., & HENNEKENS, C. H. (1998) · Survey of Anesthesiology · doi:10.1097/00132586-199806000-00060 · Cited by 506
Statins for Improving Renal Outcomes: A Meta-Analysis
Sandhu, S., Wiebe, N., Fried, L. F., & Tonelli, M. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006010012 · Cited by 478
End-Stage Renal Disease in the United States: An Update from the United States Renal Data System
Foley, R. N., & Collins, A. J. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007020220 · Cited by 459
The Value of Lowering Cholesterol after Myocardial Infarction
Rossouw, J. E., Lewis, B., & Rifkind, B. M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010183231606 · Cited by 410
Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?
Robinson, J. G., Smith, B., Maheshwari, N., & Schrott, H. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.085 · Cited by 407
European Best Practice Guidelines for Renal Transplantation (Part 2).
Berthoux, F. C., Abramowicz, D., Ekberg, H., Frei, U. A., Morales, J., Ølgaard, K., Paul, L., & Pontecelli, C. (2002) · Lund University Publications (Lund University) · Cited by 371
Costa, J., Borges, M., David, C., & Carneiro, A. V. (2006) · BMJ · doi:10.1136/bmj.38793.468449.ae · Cited by 340
Jungers, P., Massy, Z., Khoa, T., Fumeron, C., Labrunie, M., Lacour, B., Descamps-Latscha, B., & Man, N. (1997) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/12.12.2597 · Cited by 321
Study of Heart and Renal Protection (SHARP)
Baigent, C., & Landry, M. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s84.4.x · Cited by 320
HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients
Seliger, S. L., Weiss, N. S., Gillen, D. L., Kestenbaum, B., Ball, A., Sherrard, D. J., & Stehman-Breen, C. O. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00109.x · Cited by 294
Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients
Mallamaci, F., Zoccali, C., Tripepi, G., Fermo, I., Benedetto, F. A., Cataliotti, A., Bellanuova, I., Malatino, L. S., & Soldarini, A. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00144.x · Cited by 286
Meta-Analysis: The Effect of Statins on Albuminuria
Douglas, K., O'Malley, P. G., & Jackson, J. L. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-2-200607180-00009 · Cited by 247
SECTION IV: Long-term management of the transplant recipient
(2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.suppl_4.3 · Cited by 243
Lipid Abnormalities in the Nephrotic Syndrome: Causes, Consequences, and Treatment
Wheeler, D. C., & Bernard, D. B. (1994) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80994-2 · Cited by 194
Hebert, P. R. (1997) · JAMA · doi:10.1001/jama.278.4.313 · Cited by 162
HMG CoA reductase inhibitors (statins) for dialysis patients
Navaneethan, S. D., Nigwekar, S. U., Perkovic, V., Johnson, D. W., Craig, J. C., & Strippoli, G. F. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004289.pub3 · Cited by 158
Self-citationThe role of lipids in renal disease: Future challenges
Keane, W. F. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.07503.x · Cited by 155
Lipid-lowering therapy in patients with renal disease
Massy, Z. A., Ma, J. Z., Louis, T. A., & Kasiske, B. L. (1995) · Kidney International · doi:10.1038/ki.1995.284 · Cited by 135
Lin, J., Hu, F. B., Rimm, E. B., Rifai, N., & Curhan, G. C. (2006) · Kidney International · doi:10.1038/sj.ki.5000021 · Cited by 78
Effects of statins on inflammation in patients with acute and chronic coronary syndromes
Kinlay, S., & Selwyn, A. P. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03268-x · Cited by 70
Renal Dysfunction Does Not Alter the Pharmacokinetics or LDL‐Cholesterol Reduction of Atorvastatin
Stern, R. H., Yang, B. ‐., Horton, M. W., Moore, S., Abel, R. B., & Olson, S. C. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb05629.x · Cited by 69
Are 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors Renoprotective?
Campese, V. M., Nadim, M. K., & Epstein, M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004110958 · Cited by 67
Beneficial Effects of Statins in Coronary Artery Disease — Beyond Lowering Cholesterol
Sotiriou, C. G., & Cheng, J. W. M. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.10124 · Cited by 57
Single‐Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal Impairment
Halstenson, C. E., Triscari, J. M., DeVault, A. R., Shapiro, B. E., Keane, W. F., & Pan, H. (1992) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1992.tb03816.x · Cited by 53
Why do we need a statin trial in hemodialysis patients?
Fellström, B., Holdaas, H., & Jardine, A. G. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s84.10.x · Cited by 52
Sica, D. A., & Gehr, T. W. B. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200203000-00001 · Cited by 35
Atorvastatin in Patients With Type 2 Diabetes Mellitus Undergoing Hemodialysis
Wanner, C., Krane, V., & März, W. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.09.027 · Cited by 35
Kong, S. X., Crawford, S. Y., Gandhi, S., Seeger, J. D., Schumock, G. T., Lam, N. P., Stubbings, J., & Schoen, M. D. (1997) · Clinical Therapeutics · doi:10.1016/s0149-2918(97)80102-6 · Cited by 34
Cited by
Dissemination and publication of research findings: an updated review of related biases
Song, F., Parekh, Hooper, L., Loke, Y., Ryder, J., Sutton, A., Hing, C., Kwok, C., Pang, C., & Harvey, I. (2010) · Health Technology Assessment · doi:10.3310/hta14080 · Cited by 1,039
Brugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792
Tonelli, M., Muntner, P., Lloyd, A., Manns, B. J., Klarenbach, S., Pannu, N., James, M. T., & Hemmelgarn, B. R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60572-8 · Cited by 718
Early recognition and prevention of chronic kidney disease
James, M. T., Hemmelgarn, B. R., & Tonelli, M. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62004-3 · Cited by 606
Low glomerular filtration rate and risk of stroke: meta-analysis
Lee, M., Saver, J. L., Chang, K.-H., Liao, H.-W., Chang, S.-C., & Ovbiagele, B. (2010) · BMJ · doi:10.1136/bmj.c4249 · Cited by 466
Metadata
- Authors
- Strippoli, G. F. M., Navaneethan, S. D., Johnson, D. W., Perkovic, V., Pellegrini, F., Nicolucci, A., & Craig, J. C.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2008-02-25
- Volume
- 336
- Issue
- 7645
- Pages
- 645-651
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- OpenAlex
- W1993266652
- Cited by
- 402
- References
- 43
- FWCI
- 57.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.